Company Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.
The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy.
The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
| Country | United States |
| IPO Date | Nov 14, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 486 |
| CEO | Thane Wettig |
Contact Details
Address: 409 Illinois Street San Francisco, California United States | |
| Website | https://www.fibrogen.com |
Stock Details
| Ticker Symbol | FGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000921299 |
| CUSIP Number | 31572Q808 |
| ISIN Number | US31572Q8087 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thane Wettig | Chief Executive Officer & Director |
| Juan Graham | Senior Vice President & Chief Financial Officer |
| Michael D. Lowenstein J.D., Ph.D. | Chief Legal Officer |
| Tricia Stewart | Chief People Officer |
| Christine L. Chung | Senior Vice President of China Operations |
| David DeLucia | Vice President of Corporate FP&A and Investor Relations |
| Dr. Barry A. Berkowitz Ph.D. | Founder |
| Dr. Elizabeth Bearby Pharm.D. | Senior Vice President of Regulatory, Biometrics, Scientific Communications & Clinical Project Management |
| Julian N. Stern | Secretary |
| Kirk A. Christoffersen MBA | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 3 | Filing |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |